Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer, offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This narrative review explores key predictive factors influencing the efficacy of ADCs, focusing on HER2-targeted therapies, such as trastuzumab emtansine and trastuzumab deruxtecan, as well as sacituzumab govitecan for triple-negative breast cancer. HER2 expression, TROP-2 levels, hormone receptor status, and the tumor microenvironment emerge as critical biomarkers for patient selection and therapeutic outcomes.
View Article and Find Full Text PDFIntroduction: This retrospective study and review aim to investigate diffuse adult gliomas in the motor cortex (primary motor area, M1, and secondary motor area, M2, which includes the supplementary motor area and premotor cortex). It explores the relationships between the histologic and molecular profiles of the lesions, their location, and the type of resection performed, and correlates them with patients' outcomes post-surgery.
Material And Methods: An Institutional retrospective review was conducted on a consecutive series of 200 selected patients with histologically confirmed Glioblastomas (GBM) treated surgically between September 2018 and February 2022.